Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6

Area of Science:

• Virology
• Medicinal Chemistry
• Biochemistry

Background:

• Hepatitis C virus (HCV) infection is a major global health concern.
• Benzohydroxamic acids (BHAs) have been identified as promising inhibitors of HCV replication.
• Understanding the mechanisms of antiviral activity is crucial for developing new therapeutics.

Purpose of the Study:

• To synthesize and evaluate pyridine hydroxamic acids (PHAs) for anti-HCV activity.
• To compare the efficacy of PHAs with BHAs against HCV.
• To investigate the molecular targets and selectivity of these hydroxamic acid derivatives.

Main Methods:

• Synthesis of 12 pyridine hydroxamic acid compounds.
• Full-genome HCV replicon assay for antiviral testing.
• Analysis of α-tubulin hyperacetylation to identify molecular targets.
• Testing against poliovirus to assess selectivity.

Main Results:

• Pyridine hydroxamic acids (PHAs) demonstrated potent and selective inhibition of HCV replicon propagation.
• PHAs exhibited anti-HCV properties comparable to previously reported benzohydroxamic acids (BHAs).
• Both BHA and PHA classes induced α-tubulin hyperacetylation, indicating inhibition of histone deacetylase 6 (HDAC6).
• The tested compounds showed high selectivity, as they did not inhibit poliovirus replication.

Conclusions:

• Pyridine hydroxamic acids are effective inhibitors of hepatitis C virus.
• Inhibition of histone deacetylase 6 (HDAC6) is a key mechanism underlying the antiviral activity of these compounds.
• The high selectivity against HCV suggests potential for therapeutic development.